These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 35074332)

  • 61. Engineering viral genomics and nano-liposomes in microfluidic platforms for patient-specific analysis of SARS-CoV-2 variants.
    Satta S; Shahabipour F; Gao W; Lentz SR; Perlman S; Ashammakhi N; Hsiai T
    Theranostics; 2022; 12(10):4779-4790. PubMed ID: 35832078
    [TBL] [Abstract][Full Text] [Related]  

  • 62. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
    Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
    J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice.
    González-Domínguez I; Martínez JL; Slamanig S; Lemus N; Liu Y; Lai TY; Carreño JM; Singh G; Singh G; Schotsaert M; Mena I; McCroskery S; Coughlan L; Krammer F; García-Sastre A; Palese P; Sun W
    Microbiol Spectr; 2022 Jun; 10(3):e0153822. PubMed ID: 35658571
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Modelling direct and herd protection effects of vaccination against the SARS-CoV-2 Delta variant in Australia.
    McBryde ES; Meehan MT; Caldwell JM; Adekunle AI; Ogunlade ST; Kuddus MA; Ragonnet R; Jayasundara P; Trauer JM; Cope RC
    Med J Aust; 2021 Nov; 215(9):427-432. PubMed ID: 34477236
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice.
    Hu L; Xu Y; Wu L; Feng J; Zhang L; Tang Y; Zhao X; Mai R; Chen L; Mei L; Tan Y; Du Y; Zhen Y; Su W; Peng T
    Viruses; 2022 Apr; 14(5):. PubMed ID: 35632595
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants.
    Chakraborty C; Sharma AR; Bhattacharya M; Agoramoorthy G; Lee SS
    mBio; 2021 Aug; 12(4):e0114021. PubMed ID: 34465019
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Comparative characterization of antibody responses induced by Ad5-vectored spike proteins of emerging SARS-CoV-2 VOCs.
    Wang B; Xu J; Wu S; Zhang Z; Zhao Z; Zhang J; Fu L; Zai X; Wang Y; Zhang G; Chen Z; Chen Y; Sun H; Song X; Zhang J; Zhu L; Hou L; Chen W
    Signal Transduct Target Ther; 2022 Jul; 7(1):257. PubMed ID: 35906201
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Third Wave of the COVID-19 Pandemic: Prominence of Initial Public Health Interference.
    Mukherjee S; Ray SK
    Infect Disord Drug Targets; 2022; 22(4):e080222200919. PubMed ID: 35135456
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Facing the wrath of enigmatic mutations: a review on the emergence of severe acute respiratory syndrome coronavirus 2 variants amid coronavirus disease-19 pandemic.
    Chadha J; Khullar L; Mittal N
    Environ Microbiol; 2022 Jun; 24(6):2615-2629. PubMed ID: 34320263
    [TBL] [Abstract][Full Text] [Related]  

  • 71. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.
    Narowski TM; Raphel K; Adams LE; Huang J; Vielot NA; Jadi R; de Silva AM; Baric RS; Lafleur JE; Premkumar L
    Cell Rep; 2022 Feb; 38(5):110336. PubMed ID: 35090596
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review.
    SeyedAlinaghi S; Mirzapour P; Dadras O; Pashaei Z; Karimi A; MohsseniPour M; Soleymanzadeh M; Barzegary A; Afsahi AM; Vahedi F; Shamsabadi A; Behnezhad F; Saeidi S; Mehraeen E; Shayesteh Jahanfar
    Eur J Med Res; 2021 Jun; 26(1):51. PubMed ID: 34103090
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Differences in Transmission between SARS-CoV-2 Alpha (B.1.1.7) and Delta (B.1.617.2) Variants.
    Trobajo-Sanmartín C; Martínez-Baz I; Miqueleiz A; Fernández-Huerta M; Burgui C; Casado I; Baigorría F; Navascués A; Castilla J; Ezpeleta C
    Microbiol Spectr; 2022 Apr; 10(2):e0000822. PubMed ID: 35412379
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Influence of SARS-CoV-2 Variant B.1.1.7, Vaccination, and Public Health Measures on the Spread of SARS-CoV-2.
    Dimeglio C; Milhes M; Loubes JM; Ranger N; Mansuy JM; Trémeaux P; Jeanne N; Latour J; Nicot F; Donnadieu C; Izopet J
    Viruses; 2021 May; 13(5):. PubMed ID: 34066231
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Genomic characterization unravelling the causative role of SARS-CoV-2 Delta variant of lineage B.1.617.2 in 2nd wave of COVID-19 pandemic in Chhattisgarh, India.
    Singh P; Sharma K; Singh P; Bhargava A; Negi SS; Sharma P; Bhise M; Tripathi MK; Jindal A; Nagarkar NM
    Microb Pathog; 2022 Mar; 164():105404. PubMed ID: 35065253
    [TBL] [Abstract][Full Text] [Related]  

  • 77. COVID-19 vaccination and SARS-CoV-2 Omicron (B.1.1.529) variant: a light at the end of the tunnel?
    Mattiuzzi C; Henry BM; Lippi G
    Int J Infect Dis; 2022 May; 118():167-168. PubMed ID: 35278677
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
    Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO
    mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The variants question: What is the problem?
    Zella D; Giovanetti M; Benedetti F; Unali F; Spoto S; Guarino M; Angeletti S; Ciccozzi M
    J Med Virol; 2021 Dec; 93(12):6479-6485. PubMed ID: 34255352
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa.
    Viana R; Moyo S; Amoako DG; Tegally H; Scheepers C; Althaus CL; Anyaneji UJ; Bester PA; Boni MF; Chand M; Choga WT; Colquhoun R; Davids M; Deforche K; Doolabh D; du Plessis L; Engelbrecht S; Everatt J; Giandhari J; Giovanetti M; Hardie D; Hill V; Hsiao NY; Iranzadeh A; Ismail A; Joseph C; Joseph R; Koopile L; Kosakovsky Pond SL; Kraemer MUG; Kuate-Lere L; Laguda-Akingba O; Lesetedi-Mafoko O; Lessells RJ; Lockman S; Lucaci AG; Maharaj A; Mahlangu B; Maponga T; Mahlakwane K; Makatini Z; Marais G; Maruapula D; Masupu K; Matshaba M; Mayaphi S; Mbhele N; Mbulawa MB; Mendes A; Mlisana K; Mnguni A; Mohale T; Moir M; Moruisi K; Mosepele M; Motsatsi G; Motswaledi MS; Mphoyakgosi T; Msomi N; Mwangi PN; Naidoo Y; Ntuli N; Nyaga M; Olubayo L; Pillay S; Radibe B; Ramphal Y; Ramphal U; San JE; Scott L; Shapiro R; Singh L; Smith-Lawrence P; Stevens W; Strydom A; Subramoney K; Tebeila N; Tshiabuila D; Tsui J; van Wyk S; Weaver S; Wibmer CK; Wilkinson E; Wolter N; Zarebski AE; Zuze B; Goedhals D; Preiser W; Treurnicht F; Venter M; Williamson C; Pybus OG; Bhiman J; Glass A; Martin DP; Rambaut A; Gaseitsiwe S; von Gottberg A; de Oliveira T
    Nature; 2022 Mar; 603(7902):679-686. PubMed ID: 35042229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.